Discovery Laboratories, Inc. (DSCO) said it has submitted to the U.S. Food and Drug Administration its proposed protocol for a Surfaxin limited clinical trial. The protocol incorporates a clinical trial design that is primarily intended to assess a pharmacodynamic, or PD, response following Surfaxin administration in preterm infants with Respiratory Distress Syndrome, or RDS.
Discovery Labs proposed this trial design in response to a comment by the FDA that a limited clinical trial could potentially resolve the key remaining issue for approval of Surfaxin for the prevention of RDS in premature infants.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.